Published in Nat Rev Immunol on January 01, 2008
Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science (2009) 3.47
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression. Cell (2015) 3.03
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
The two faces of interferon-γ in cancer. Clin Cancer Res (2011) 2.20
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication. Immunol Rev (2011) 2.02
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest (2011) 1.91
Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. Immunity (2013) 1.80
A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. Clin Cancer Res (2009) 1.79
Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A (2011) 1.78
Induction of IDO by bacille Calmette-Guérin is responsible for development of murine depressive-like behavior. J Immunol (2009) 1.77
The immunity-related GTPase Irgm1 promotes the expansion of activated CD4+ T cell populations by preventing interferon-gamma-induced cell death. Nat Immunol (2008) 1.73
Plasticity of tumour and immune cells: a source of heterogeneity and a cause for therapy resistance? Nat Rev Cancer (2013) 1.61
Modulators of arginine metabolism support cancer immunosurveillance. BMC Immunol (2009) 1.61
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer. Cancer Immunol Immunother (2014) 1.39
NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction. Biol Blood Marrow Transplant (2010) 1.38
Dendritic cells, indoleamine 2,3 dioxygenase and acquired immune privilege. Int Rev Immunol (2010) 1.29
Physiologic control of IDO competence in splenic dendritic cells. J Immunol (2011) 1.29
Myeloid-derived suppressor cells: general characteristics and relevance to clinical management of pancreatic cancer. Curr Cancer Drug Targets (2011) 1.22
Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol (2010) 1.22
IDO: a double-edged sword for T(H)1/T(H)2 regulation. Immunol Lett (2008) 1.21
Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression. J Infect Dis (2011) 1.18
Metabolic reprogramming and metabolic dependency in T cells. Immunol Rev (2012) 1.18
B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2010) 1.15
What causes alopecia areata? Exp Dermatol (2013) 1.14
IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation. Int Immunol (2014) 1.13
Tissue engineering tools for modulation of the immune response. Biotechniques (2011) 1.12
Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. Gastroenterology (2015) 1.12
Targeting the immunoregulatory indoleamine 2,3 dioxygenase pathway in immunotherapy. Immunotherapy (2009) 1.10
CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol (2013) 1.08
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvate. Cancer Res (2010) 1.06
Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2015) 1.06
Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol (2014) 1.04
Advancing islet transplantation: from engraftment to the immune response. Diabetologia (2011) 1.04
Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One (2012) 1.02
Dendritic cells as targets for therapy in rheumatoid arthritis. Nat Rev Rheumatol (2009) 1.02
The missing link between indoleamine 2,3-dioxygenase mediated antibacterial and immunoregulatory effects. J Cell Mol Med (2009) 1.01
Immunity of human epithelial ovarian carcinoma: the paradigm of immune suppression in cancer. J Transl Med (2013) 1.01
Cancer: Why tumours eat tryptophan. Nature (2011) 0.99
Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy. Front Oncol (2013) 0.99
Arginine deprivation and immune suppression in a mouse model of Alzheimer's disease. J Neurosci (2015) 0.96
M. tuberculosis induces potent activation of IDO-1, but this is not essential for the immunological control of infection. PLoS One (2012) 0.96
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
Different partners, opposite outcomes: a new perspective of the immunobiology of indoleamine 2,3-dioxygenase. Mol Med (2012) 0.95
Induction and role of indoleamine 2,3 dioxygenase in mouse models of influenza a virus infection. PLoS One (2013) 0.94
A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors. Oncotarget (2014) 0.94
Curing mice with large tumors by locally delivering combinations of immunomodulatory antibodies. Clin Cancer Res (2014) 0.94
Regulation and privilege in transplantation tolerance. J Clin Immunol (2008) 0.93
Generation of immunogenic and tolerogenic clinical-grade dendritic cells. Immunol Res (2011) 0.93
Networked T cell death following macrophage infection by Mycobacterium tuberculosis. PLoS One (2012) 0.91
In vivo T cell activation in lymphoid tissues is inhibited in the oxygen-poor microenvironment. Front Immunol (2011) 0.90
The SOCS3-independent expression of IDO2 supports the homeostatic generation of T regulatory cells by human dendritic cells. J Immunol (2014) 0.89
Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment. Front Oncol (2014) 0.89
Deficient tryptophan catabolism along the kynurenine pathway reveals that the epididymis is in a unique tolerogenic state. J Biol Chem (2010) 0.89
Immune escape mechanisms as a guide for cancer immunotherapy. Clin Cancer Res (2014) 0.88
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol (2016) 0.88
Good news-bad news: the Yin and Yang of immune privilege in the eye. Front Immunol (2012) 0.88
The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol (2009) 0.88
Nodal metastasis in cervical cancer occurs in clearly delineated fields of immune suppression in the pelvic lymph catchment area. Oncotarget (2015) 0.87
Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model. PLoS One (2010) 0.87
Pathogenic antibodies are active participants in spinal cord injury. J Clin Invest (2009) 0.86
Immunity and tolerance to fungi in hematopoietic transplantation: principles and perspectives. Front Immunol (2012) 0.86
IDO-Mediated Tryptophan Degradation in the Pathogenesis of Malignant Tumor Disease. Int J Tryptophan Res (2010) 0.86
Immune heterogeneity in neuroinflammation: dendritic cells in the brain. J Neuroimmune Pharmacol (2012) 0.86
The immunosuppressive side of PDT. Photochem Photobiol Sci (2011) 0.86
The Role of the Immune Response in Chlamydia trachomatis Infection of the Male Genital Tract: A Double-Edged Sword. Front Immunol (2014) 0.85
Role of neuroinflammation in the emotional and cognitive alterations displayed by animal models of obesity. Front Neurosci (2015) 0.85
Altered tryptophan metabolism as a paradigm for good and bad aspects of immune privilege in chronic inflammatory diseases. Front Immunol (2012) 0.85
Small intestine CD11c+ CD8+ T cells suppress CD4+ T cell-induced immune colitis. Am J Physiol Gastrointest Liver Physiol (2011) 0.85
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase. Cancer Immunol Immunother (2012) 0.84
Intracellular B7-H4 suppresses bile duct epithelial cell apoptosis in human primary biliary cirrhosis. Inflammation (2011) 0.83
HLA antigen and NK cell activating ligand expression in malignant cells: a story of loss or acquisition. Semin Immunopathol (2011) 0.83
Autoimmunity as a double agent in tumor killing and cancer promotion. Front Immunol (2014) 0.83
Immune Tolerance for Autoimmune Disease and Cell Transplantation. Annu Rev Biomed Eng (2016) 0.83
Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. Pharmacol Ther (2016) 0.82
PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes. Tissue Eng Part A (2013) 0.82
Interplay of macrophages and T cells in the lung vasculature. Am J Physiol Lung Cell Mol Physiol (2012) 0.81
IDO in human gut graft-versus-host disease. Biol Blood Marrow Transplant (2011) 0.80
Hypoxia-induced and A2A adenosine receptor-independent T-cell suppression is short lived and easily reversible. Int Immunol (2013) 0.80
The Role of CD4 T Cell Memory in Generating Protective Immunity to Novel and Potentially Pandemic Strains of Influenza. Front Immunol (2016) 0.79
Modulation of tumor tolerance in primary central nervous system malignancies. Clin Dev Immunol (2012) 0.79
The role of indoleamine 2, 3 dioxygenase in regulating host immunity to leishmania infection. J Biomed Sci (2012) 0.79
Hypoxic stress: obstacles and opportunities for innovative immunotherapy of cancer. Oncogene (2016) 0.78
Intrinsic and Tumor Microenvironment-Induced Metabolism Adaptations of T Cells and Impact on Their Differentiation and Function. Front Immunol (2016) 0.78
Lineage-specific transcription factors in unexpected places. Eur J Immunol (2010) 0.78
The potential role of indoleamine 2,3 dioxygenase (IDO) as a predictive and therapeutic target for diabetes treatment: a mythical truth. EPMA J (2010) 0.77
A potential role of indoleamine 2,3-dioxygenase-specific T cells in leishmania vaccination. J Infect Dis (2011) 0.76
The Kynurenine Pathway Is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy. Int J Tryptophan Res (2016) 0.76
Specific in situ detection of murine indoleamine 2, 3-dioxygenase. J Cell Biochem (2014) 0.76
Clinical Development of the E75 Vaccine in Breast Cancer. Breast Care (Basel) (2016) 0.75
N-Dihydrogalactochitosan as a potent immune activator for dendritic cells. J Biomed Mater Res A (2016) 0.75
Advances in islet encapsulation technologies. Nat Rev Drug Discov (2016) 0.75
Association of Interferon Gamma +874T/A Polymorphism and Leukemia Risk: A Meta-Analysis. Medicine (Baltimore) (2016) 0.75
New insights into mononuclear phagocyte biology from the visual system. Nat Rev Immunol (2017) 0.75
Lactobacillus acidophilus L-92 Cells Activate Expression of Immunomodulatory Genes in THP-1 Cells. Biosci Microbiota Food Health (2014) 0.75
IDO expression by dendritic cells: tolerance and tryptophan catabolism. Nat Rev Immunol (2004) 10.08
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest (2007) 4.44
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res (2007) 3.44
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood (2011) 3.18
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
IDO activates regulatory T cells and blocks their conversion into Th17-like T cells. J Immunol (2009) 2.83
The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation. J Immunol (2008) 2.55
Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol (2003) 2.54
Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling. J Immunol (2005) 2.51
Indoleamine 2,3-dioxygenase expression is restricted to fetal trophoblast giant cells during murine gestation and is maternal genome specific. J Reprod Immunol (2004) 2.30
Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A (2008) 2.18
A minor population of splenic dendritic cells expressing CD19 mediates IDO-dependent T cell suppression via type I IFN signaling following B7 ligation. Int Immunol (2005) 2.18
Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses. J Immunol (2002) 2.14
Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol (2004) 2.13
Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med (2013) 2.13
Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood (2007) 2.12
Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer (2002) 2.10
An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos. Immunity (2013) 1.98
Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood (2009) 1.93
The countervailing actions of myeloid and plasmacytoid dendritic cells control autoimmune diabetes in the nonobese diabetic mouse. J Immunol (2007) 1.89
Opposing biological functions of tryptophan catabolizing enzymes during intracellular infection. J Infect Dis (2011) 1.86
Genome-wide DNA methylation analysis reveals novel epigenetic changes in chronic lymphocytic leukemia. Epigenetics (2012) 1.80
Tryptophan deprivation sensitizes activated T cells to apoptosis prior to cell division. Immunology (2002) 1.57
Inhibition of indoleamine 2,3-dioxygenase (IDO) enhances elimination of virus-infected macrophages in an animal model of HIV-1 encephalitis. Blood (2005) 1.54
Host programmed death ligand 1 is dominant over programmed death ligand 2 expression in regulating graft-versus-host disease lethality. Blood (2013) 1.44
Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest (2014) 1.38
IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology (2012) 1.37
Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2012) 1.37
Tryptophan catabolism and regulation of adaptive immunity. J Immunol (2003) 1.36
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. Blood (2009) 1.35
Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia. Blood (2009) 1.35
Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol (2007) 1.32
Physiologic control of IDO competence in splenic dendritic cells. J Immunol (2011) 1.29
Cell-autonomous control of interferon type I expression by indoleamine 2,3-dioxygenase in regulatory CD19+ dendritic cells. Eur J Immunol (2007) 1.27
Generation of cytotoxic T cells against virus-infected human brain macrophages in a murine model of HIV-1 encephalitis. J Immunol (2002) 1.23
Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma. Lab Invest (2003) 1.23
Indoleamine 2,3-dioxygenase in lung dendritic cells promotes Th2 responses and allergic inflammation. Proc Natl Acad Sci U S A (2008) 1.22
Leishmania major attenuates host immunity by stimulating local indoleamine 2,3-dioxygenase expression. J Infect Dis (2011) 1.18
Butyrate suppresses colonic inflammation through HDAC1-dependent Fas upregulation and Fas-mediated apoptosis of T cells. Am J Physiol Gastrointest Liver Physiol (2012) 1.18
Regulation of macrophage foam cell formation by alphaVbeta3 integrin: potential role in human atherosclerosis. Am J Pathol (2004) 1.17
Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation? Blood (2011) 1.16
B-lymphoid cells with attributes of dendritic cells regulate T cells via indoleamine 2,3-dioxygenase. Proc Natl Acad Sci U S A (2010) 1.15
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Cutting edge: DNA sensing via the STING adaptor in myeloid dendritic cells induces potent tolerogenic responses. J Immunol (2013) 1.13
αVβ3 integrin regulates macrophage inflammatory responses via PI3 kinase/Akt-dependent NF-κB activation. J Cell Physiol (2011) 1.09
Engineering DNA nanoparticles as immunomodulatory reagents that activate regulatory T cells. J Immunol (2012) 1.06
Highlights of 10 years of immunology in Nature Reviews Immunology. Nat Rev Immunol (2011) 1.06
Physiologic control of the functional status of Foxp3+ regulatory T cells. J Immunol (2011) 1.05
A high-affinity, tryptophan-selective amino acid transport system in human macrophages. J Leukoc Biol (2006) 1.04
Role of CD28 in fatal autoimmune disorder in scurfy mice. Blood (2007) 1.04
Chemotherapy rescues tumor-driven aberrant CD4+ T-cell differentiation and restores an activated polyfunctional helper phenotype. Blood (2010) 1.03
Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance. Proc Natl Acad Sci U S A (2014) 1.02
Interaction of tryptophan derivatives with SLC6A14 (ATB0,+) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J (2008) 1.02
Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy. Blood (2012) 1.02
Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol (2009) 0.99
Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance. Immunol Invest (2012) 0.98
Dendritic cells have the option to express IDO-mediated suppression or not. Blood (2005) 0.96
Zinc protoporphyrin IX stimulates tumor immunity by disrupting the immunosuppressive enzyme indoleamine 2,3-dioxygenase. Mol Cancer Ther (2010) 0.94
Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine (2011) 0.92
Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol (2013) 0.89
Deficient tryptophan catabolism along the kynurenine pathway reveals that the epididymis is in a unique tolerogenic state. J Biol Chem (2010) 0.89
GCN2-dependent metabolic stress is essential for endotoxemic cytokine induction and pathology. Mol Cell Biol (2013) 0.89
Indoleamine 2,3-dioxygenase, immunosuppression and pregnancy. J Reprod Immunol (2002) 0.86
Inhibiting retinoic acid signaling ameliorates graft-versus-host disease by modifying T-cell differentiation and intestinal migration. Blood (2013) 0.85
IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol (2009) 0.83
Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J Clin Invest (2016) 0.83
Indoleamine 2,3-dioxygenase 1 (ido1) is involved in the control of mouse caput epididymis immune environment. PLoS One (2013) 0.81
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
Modulation of tumor tolerance in primary central nervous system malignancies. Clin Dev Immunol (2012) 0.79
Immunological concerns with bioengineering approaches. Ann N Y Acad Sci (2002) 0.76
Immune response to engineered tissues and cells: breakout session summary. Ann N Y Acad Sci (2002) 0.75